抗阻训练对结肠癌炎症生物标志物的影响及其与治疗结果的关联
Impact of resistance training on inflammatory biomarkers and associations with treatment outcomes in colon cancer.
作者信息
Lee Seohyuk, Ma Chao, Caan Bette J, Binder Alexandra M, Brown Justin C, Pena Perez Amalia, Lee Catherine, Weltzien Erin, Ross Michelle C, Quesenberry Charles P, Campbell Kristin L, Cespedes Feliciano Elizabeth M, Castillo Adrienne, Schmitz Kathryn H, Meyerhardt Jeffrey A
机构信息
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
出版信息
Cancer. 2025 May 1;131(9):e35865. doi: 10.1002/cncr.35865.
INTRODUCTION
Among patients with colon cancer undergoing adjuvant chemotherapy, the impact of resistance training with supplemental dietary protein on inflammatory changes during treatment, whether baseline or changes in inflammatory markers are associated with relative dose intensity (RDI), and the associations of inflammation with body composition were investigated.
METHODS
A multicenter randomized clinical trial of 174 patients with colon cancer undergoing adjuvant chemotherapy assigned to a home-based resistance training program or usual care was conducted. High-sensitivity C-reactive protein (hsCRP), interleukin-6, tumor necrosis factor-α receptor-II, and growth differentiation factor-15 levels were assessed preintervention and following chemotherapy completion. Baseline body composition was evaluated via dual-energy X-ray absorptiometry. Multivariate analyses were adjusted for sociodemographic and clinical factors.
RESULTS
Patients randomized to resistance training versus usual care experienced similar changes in all inflammatory markers. Those in the highest versus lowest tertile of baseline hsCRP were more likely to have received RDI >70% (odds ratio, 4.11; 95% CI, 1.29-13.1); however, changes across any of the inflammatory markers were not associated with RDI. Patients in the highest versus lowest tertiles of hsCRP, interleukin-6, and tumor necrosis factor-α receptor-II were more likely to have higher baseline body mass index, total lean mass, and total fat mass.
CONCLUSION
Inflammatory markers in patients with colon cancer undergoing adjuvant chemotherapy were not significantly impacted by randomization to a resistance training program but were associated with baseline body composition measures. Further investigations are needed to better elucidate the potential role of inflammatory markers and body composition in predicting important treatment outcomes.
CLINICALTRIALS
GOV: NCT03291951.
引言
在接受辅助化疗的结肠癌患者中，研究了补充膳食蛋白质的抗阻训练对治疗期间炎症变化的影响，基线或炎症标志物的变化是否与相对剂量强度（RDI）相关，以及炎症与身体成分的关联。
方法
对174例接受辅助化疗的结肠癌患者进行了一项多中心随机临床试验，这些患者被分配到家庭抗阻训练计划或常规护理组。在干预前和化疗完成后评估高敏C反应蛋白（hsCRP）、白细胞介素-6、肿瘤坏死因子-α受体-II和生长分化因子-15水平。通过双能X线吸收法评估基线身体成分。多变量分析对社会人口统计学和临床因素进行了调整。
结果
随机分配到抗阻训练组与常规护理组的患者在所有炎症标志物上经历了相似的变化。基线hsCRP处于最高三分位数与最低三分位数的患者接受RDI>70%的可能性更高（比值比，4.11；95%CI，1.29-13.1）；然而，任何炎症标志物的变化均与RDI无关。hsCRP、白细胞介素-6和肿瘤坏死因子-α受体-II处于最高三分位数与最低三分位数的患者更有可能具有更高的基线体重指数、总瘦体重和总脂肪量。
结论
接受辅助化疗的结肠癌患者的炎症标志物并未因随机分配到抗阻训练计划而受到显著影响，但与基线身体成分测量值相关。需要进一步研究以更好地阐明炎症标志物和身体成分在预测重要治疗结果中的潜在作用。
临床试验
GOV：NCT03291951。
Zotero 插件